ESMO 2024 Insights: POD1UM-303/InterAACT 2 Study: Retifanlimab With Carboplatin-Paclitaxel in Pts With Inoperable Locally Recurrent or Metastatic SCC of the Anal Canal Not Previously Treated With Systemic Chemo | VuMedi

Find latest Colon Cancer videos · 300+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

10 seconds

Playback speed

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: POD1UM-303/InterAACT 2 Study: Retifanlimab With Carboplatin-Paclitaxel in Pts With Inoperable Locally Recurrent or Metastatic SCC of the Anal Canal Not Previously Treated With Systemic Chemo

By 2024 ESMO Annual Meeting Insights Hub FEATURING Sheela Rao

By 2024 ESMO Annual Meeting Insights Hub FEATURING Sheela Rao

1 view

March 28, 2025

Comments 0

Login to view comments. Click here to Login